Biotech Startups

Bioqore builds Voyager, an AI-powered closed-loop bioprocess intelligence platform that combines predictive modeling with micro-scale laboratory experiments to recommend and validate optimal process conditions for producing preclinical- and clinic-ready therapeutic candidates. It serves biotech and pharma teams working on bioprocess development, scale-up, and biomanufacturing.

3 investors

BioBrace develops a reinforced bioinductive implant combining collagen scaffolds with PLLA microfilaments to support soft tissue repair, particularly for tendon healing procedures. The product serves orthopedic surgeons and is designed for open or arthroscopic surgical applications.

3 investors

Biosphere develops bioreactors and biomanufacturing systems to modernize industrial production of chemicals, materials, foods, and pharmaceuticals using engineered biology and clean energy. The company addresses the production bottleneck in the $100b bioproducts industry by moving beyond decades-old reactor designs.

3 investors

biossil is an AI-native biopharma company developing late-stage drug programs for life-threatening conditions with unmet needs, including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. It applies gene embedding analysis to drug discovery, rescue, and repositioning, with active and planned clinical trials across a range of rare and severe indications.

3 investors

Biota develops rapid PFAS testing technologies, including field-compatible test kits and lab sample-prep products, that deliver results in about 15 minutes instead of weeks. It serves PFAS treatment companies and testing labs to speed up field monitoring and regulated confirmatory analysis for water cleanup.

3 investors

Biotic Labs develops biological processes to manufacture bio-based, biodegradable polymers that replace fossil-fuel plastics for industrial and consumer applications. The company aims to transition industries toward a sustainable, circular economy for plastic production.

3 investors

Bioventus develops and markets medical devices for active healing, including pain management, restorative therapies, and surgical solutions that aim to enhance the body's natural healing processes and reduce the need for invasive procedures. The company serves healthcare providers and patients seeking clinically effective, cost-efficient alternatives to traditional treatments.

3 investors

BIOWEG develops and sells bio-based, sustainable high-performance ingredients created by combining biotechnology, material science, and molecular simulation. Its animal- and GMO-free ingredients target companies and consumer brands in the beauty, nutraceuticals, and food/beverage sectors.

3 investors

Bioworks develops PlaX, a plant-based fiber intended as an alternative to petroleum-derived synthetic fibers, aimed at making the apparel industry more sustainable. The company targets clothing and textile manufacturers seeking lower-impact materials.

3 investors

3 investors

BMI OrganBank develops organ perfusion and preservation systems to improve transplantation outcomes and extend organ viability outside the body. The company serves transplant clinicians and researchers working to reduce organ transplant waitlists and advance regenerative medicine.

3 investors

3 investors

Bolden Therapeutics is a biotechnology company developing therapeutics that promote neurogenesis—the formation of new brain cells—to treat neurological and central nervous system diseases such as Alzheimer's. Its lead approach uses exon-skipping antisense oligonucleotides, with multiple therapeutic modalities in preclinical development.

3 investors

Boltz develops generative AI models for biomolecular design and drug discovery, used by researchers across pharmaceutical, biotech, agricultural, and academic sectors. The company offers frontier foundation models for protein and small-molecule design through an API with enterprise deployment options.

3 investors

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.

3 investors

Bota offers engineered protein solutions through strain optimization and screening, leveraging proprietary datasets to increase protein yield while reducing production costs for industrial biotech applications.

3 investors

Botalys develops a platform for creating rare botanical ingredients tailored for nutraceutical and cosmetic applications through structured co-development partnerships with industry leaders. The platform guides partners through plant selection, validation, sourcing, cultivation, and industrial-scale production of specialized botanical ingredients.

3 investors

BrainsGate develops a neurostimulation therapy for stroke patients based on stimulation of the sphenopalatine ganglion (SPG) to increase cerebral blood flow. The company operates in the medical device field, having conducted the ImpACT-24 clinical studies for acute ischemic stroke treatment.

3 investors

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.

3 investors

Breakout is a venture capital firm that has invested for over a decade in science-driven technology companies across biotech, tech-bio, deep tech, and hard tech. It partners with founders scaling scientific innovation and connects them to corporates, strategic partners, and next-stage investors.

3 investors

BreezeBio develops a programmable delivery platform called NanoGalaxy for targeted delivery of genetic medicines to specific cells and tissues. The platform addresses the challenge of enabling genetic payloads to reach their target sites in the body to control biological processes.

3 investors

Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.

3 investors

BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.

3 investors

Briya builds a data exchange infrastructure that connects healthcare organizations and life sciences organizations to share high-quality medical and clinical data securely and compliantly. The platform is aimed at researchers and hospitals to speed access to data for medical research and treatment development.

3 investors